Abstract
The inhibition of the C-terminal domain of heat shock protein 90 (Hsp90) is emerging as a novel strategy for cancer therapy, therefore the identification of a new class of C-terminal inhibitors is strongly required.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have